Genkyotex SA.

GKTX

FR0013399474

Biotechnology & Medical Research

End-of-day quote Euronext Paris Other stock markets 06:00:00 2021-09-22 pm EDT			5-day change	1st Jan Change
3.205 ^EUR	+0.16%		+1.58%	-.--%

2021	Calliditas Therapeutics : Acquires Remaining Stake in Genkyotex	MT
2021	Genkyotex SA(ENXTPA:GKTX) dropped from CAC AllShares Index	CI

Genkyotex SA(ENXTPA:GKTX) dropped from Next Biotech Index

October 05, 2021 at 12:00 am EDT

Genkyotex SA has been removed from Next Biotech Index.

Latest news about Genkyotex SA.

Calliditas Therapeutics : Acquires Remaining Stake in Genkyotex	2021	MT
Genkyotex SA(ENXTPA:GKTX) dropped from CAC AllShares Index	2021	CI
Genkyotex SA(ENXTPA:GKTX) dropped from Next Biotech Index	2021	CI
Global markets live: Sanofi, ASML, Apple, United Airlines, Netflix...	2021
Global markets live: Airbnb, Coinbase, Walt Disney,...	2021
Genkyotex Sa Reports Earnings Results for the Full Year Ended December 31, 2020	2021	CI
Genkyotex : Chief Medical Officer Steps Down Amid Start of Phase 2/3 Study in Chronic Liver Disease	2021	MT
Genkyotex SA Announces Update for Near Term Clinical Development Plan for Setanaxib	2021	CI
Genkyotex : Reports Positive Results from Phase One Trial of Anti-fibrosis Drug Setanaxib	2021	MT
Genkyotex Announces Positive Phase 1 Results Demonstrating Favorable Safety and Pharmacokinetic Profile of High-Dose Setanaxib	2021	CI
Calliditas Therapeutics AB (OM:CALTX) completed the acquisition of 37.3% stake in Genkyotex SA.	2020	CI
Genkyotex : Setanaxib Obtains Orphan Drug Designation By European Commission	2020	MT
Genkyotex Announces Board and President Changes	2020	CI
Genkyotex Sa Reports Earnings Results for the Half Year Ended June 30, 2020	2020	CI
Genkyotex Announces the Enrollment of the 1st Patient in the Phase 2 Trial of Setanaxib in Idiopathic Pulmonary Fibrosis	2020	CI
Calliditas Therapeutics AB (OM:CALTX) made a tender offer to acquire 37.3% stake in Genkyotex SA for €12.1 million.	2020	CI
Genkyotex Announces the Dosing of the First Subjects in Its Phase 1 Study with High-Dose Setanaxib	2020	CI
Genkyotex Provides New Clinical Data from the PBC Phase 2 Trial Providing Further Evidence of the Anti-Fibrotic Activity of Setanaxib	2020	CI
Genkyotex Receives Approval From the French Medicines Agency to Initiate a Phase 1 Clinical Study With High-dose Setanaxib	2020	CI
Genkyotex SA Announces Consolidated Earnings Results for the Year Ended December 31, 2019	2020	CI
Certain Common Shares of Genkyotex SA are subject to a Lock-Up Agreement Ending on 3-MAY-2020.	2020	CI
Genkyotex’s Setanaxib Significantly Improves Immunotherapy Including Checkpoint Inhibitors in Multiple Preclinical Cancer Models	2020	CI
Genkyotex Sa Reports Earnings Results for the Full Year Ended December 31, 2019	2020	CI
Genkyotex Reports Progress of Setanaxib Phase 2 Investigator Initiated Trials	2019	CI
Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF	2019	CI

GenKyoTex SA is a France-based company involved in the biotechnology sector. The Company focuses on the development of therapies based on selective inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NOX) enzymes, which cause a range of disease processes, such as fibrosis, inflammation, pain processing, cancer development and neurodegeneration. The Company's pipeline includes GKT831, a NOX inhibitor aimed at primary biliary cholangitis (PBC) and fibrosis; GKT771, a NOX inhibitor mainly aimed at inflammatory pain and angiogenesis, and other NOX inhibitors, which target at central nervous system (CNS), hearing loss and oncology.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENKYOTEX SA.	-.--%	52 M $
SEAGEN INC.	+70.40%	41 313 M $
IQVIA HOLDINGS INC.	+5.07%	39 289 M $
MODERNA, INC.	-55.28%	30 625 M $
LONZA GROUP AG	-27.34%	27 758 M $
ICON PUBLIC LIMITED COMPANY	+40.26%	22 431 M $
ALNYLAM PHARMACEUTICALS, INC.	-28.45%	21 339 M $
CELLTRION, INC.	+4.49%	17 693 M $
UNITED THERAPEUTICS CORPORATION	-13.10%	11 356 M $
BIO-TECHNE CORPORATION	-17.58%	10 803 M $